Charles Schwab Investment Management Inc. Cuts Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)

Charles Schwab Investment Management Inc. decreased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 21.3% in the fourth quarter, HoldingsChannel reports. The fund owned 140,856 shares of the company’s stock after selling 38,166 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in USANA Health Sciences were worth $5,055,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Barclays PLC increased its position in shares of USANA Health Sciences by 111.9% during the third quarter. Barclays PLC now owns 27,737 shares of the company’s stock worth $1,052,000 after purchasing an additional 14,647 shares in the last quarter. Rhumbline Advisers increased its position in USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after buying an additional 14,068 shares in the last quarter. Principal Financial Group Inc. increased its position in USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock valued at $1,924,000 after buying an additional 1,480 shares in the last quarter. Geode Capital Management LLC raised its stake in USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after buying an additional 12,898 shares during the last quarter. Finally, State Street Corp boosted its holdings in USANA Health Sciences by 0.6% in the third quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after acquiring an additional 2,782 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

USNA has been the subject of several research analyst reports. DA Davidson decreased their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

USANA Health Sciences Stock Down 3.8 %

USANA Health Sciences stock opened at $26.21 on Wednesday. The stock has a 50-day moving average price of $31.52 and a 200 day moving average price of $35.25. The company has a market capitalization of $495.50 million, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 52 week low of $26.19 and a 52 week high of $49.78.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the sale, the insider now directly owns 12,775 shares in the company, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,920 shares of company stock worth $500,285. Insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.